by Hanna | Nov 28, 2023 | Blog Post
For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans. As a result, the legislative foundation fueling life...
by Hanna | Nov 13, 2023 | Blog Post
Over the past several decades, the U.S. life sciences ecosystem has emerged as a global leader in innovation with more than 2,300 biopharmaceutical companies spanning every state. Pro-innovation mergers and acquisitions (M&A) have been a critical component of the...
by Hanna | Nov 7, 2023 | Blog Post
Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is...
by Hanna | Oct 30, 2023 | Blog Post
In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures. The life sciences industry weathers...
by Hanna | Oct 26, 2023 | Blog Post
Following the public comment period on the FTC and DOJ’s proposed merger guidelines, leading antitrust experts and economists expressed significant concerns about the dramatic shift in competition policy that the proposal represents. In a recent panel discussion...
by Hanna | Oct 24, 2023 | Blog Post
A recent survey by the U.S. Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s (DOJ) proposed approach to review and enforcement of mergers and acquisitions (M&A). The agencies’ two proposals – the...
